Li Hongcai, Liang Jingjing, Han Mengzhen, Gao Zhenpeng
College of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, People's Republic of China.
College of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, People's Republic of China.
J Adv Res. 2025 Feb;68:43-62. doi: 10.1016/j.jare.2024.03.004. Epub 2024 Mar 11.
Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with an increasing incidence worldwide. Single drug therapy may have toxic side effects and disrupt gut microbiota balance. Polyphenols are widely used in disease intervention due to their distinctive nutritional properties and medicinal value, which a potential gut microbiota modulator. However, there is a lack of comprehensive review to explore the efficacy and mechanism of combined therapy with drugs and polyphenols for NAFLD.
Based on this, this review firstly discusses the link between NAFLD and gut microbiota, and outlines the effects of polyphenols and drugs on gut microbiota. Secondly, it examined recent advances in the treatment and intervention of NAFLD with drugs and polyphenols and the therapeutic effect of the combination of the two. Finally, we highlight the underlying mechanisms of polyphenol combined drug therapy in NAFLD. This is mainly in terms of signaling pathways (NF-κB, AMPK, Nrf2, JAK/STAT, PPAR, SREBP-1c, PI3K/Akt and TLR) and gut microbiota. Furthermore, some emerging mechanisms such as microRNA potential biomarker therapies may provide therapeutic avenues for NAFLD.
Drawing inspiration from combination drug strategies, the use of active substances in combination with drugs for NAFLD intervention holds transformative and prospective potential, both improve NAFLD and restore gut microbiota balance while reducing the required drug dosage. This review systematically discusses the bidirectional interactions between gut microbiota and NAFLD, and summarizes the potential mechanisms of polyphenol synergistic drugs in the treatment of NAFLD by modulating signaling pathways and gut microbiota. Future researches should develop multi-omics technology to identify patients who benefit from polyphenols combination drugs and devising individualized treatment plans to enhance its therapeutic effect.
非酒精性脂肪性肝病(NAFLD)是一种常见的慢性肝病,在全球范围内发病率不断上升。单一药物治疗可能会产生毒副作用并破坏肠道微生物群平衡。多酚因其独特的营养特性和药用价值而被广泛用于疾病干预,是一种潜在的肠道微生物群调节剂。然而,目前缺乏对药物与多酚联合治疗NAFLD的疗效和机制的全面综述。
基于此,本综述首先讨论NAFLD与肠道微生物群之间的联系,并概述多酚和药物对肠道微生物群的影响。其次,研究了药物和多酚治疗及干预NAFLD的最新进展以及两者联合的治疗效果。最后,我们强调了多酚联合药物治疗NAFLD的潜在机制。这主要涉及信号通路(NF-κB、AMPK、Nrf2、JAK/STAT、PPAR、SREBP-1c、PI3K/Akt和TLR)和肠道微生物群。此外,一些新兴机制,如微小RNA潜在生物标志物疗法,可能为NAFLD提供治疗途径。
从联合用药策略中获得灵感,使用活性物质与药物联合干预NAFLD具有变革性和前瞻性潜力,既能改善NAFLD又能恢复肠道微生物群平衡,同时减少所需药物剂量。本综述系统地讨论了肠道微生物群与NAFLD之间的双向相互作用,并总结了多酚协同药物通过调节信号通路和肠道微生物群治疗NAFLD的潜在机制。未来的研究应开发多组学技术,以识别从多酚联合药物中获益的患者,并制定个性化治疗方案以增强其治疗效果。